Implant Sciences to deploy QS-B220 explosives detectors in Norway

Implant Sciences has won a major European tender to supply 66 QS-B220 explosives trace detection systems in Norway, as part of efforts to support new EU aviation security initiatives.

Deliveries have already commenced and the systems will be deployed for passenger and baggage screening in an airport environment.

Implant Sciences Global Sales and Marketing vice-president Dr Darryl Jones said: "We estimate that the near-term market for new trace detection screening programmes in aviation security in Europe will exceed $45m.

"Implant Sciences’ leadership in non-radioactive ion mobility spectrometry technology has been demonstrated in passing the ECAC Common Evaluation Protocol on the first try, as well as in numerous airport trials.

"We believe our field-proven reliability and low false alarm rates will lead to even more airports selecting Implant Sciences as their preferred ETD vendor."

Introduced in May 2011, the Quantum Sniffer QS-B220 is a desktop explosives and narcotics trace detector integrated with a high-resolution colour touch-screen that provides audio and visual alarm indications, including substance identification.

Using non-radioactive Ion Mobility Spectrometry (IMS) analysis technology, the QS-B220 can quickly detect and identify trace amounts of a range of military, commercial, and homemade explosives, including narcotic substances.

Designed with an automatic internal self-calibration, the detector eliminates issues such as licencing, inspection, transport, and end-of life, while providing freedom from radioactive materials, low total cost of ownership, and high operational availability.

Implant Sciences manufactures explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications.